RHUMBLINE ADVISERS - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 60 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 1.9%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,665
-25.0%
1,2910.0%0.00%
Q2 2023$2,220
-98.8%
1,291
-98.1%
0.00%
Q1 2022$180,000
-37.9%
67,376
+0.6%
0.00%
Q4 2021$290,000
-16.2%
66,948
-1.4%
0.00%
Q3 2021$346,000
-14.8%
67,933
+5.9%
0.00%
-100.0%
Q2 2021$406,000
-13.8%
64,176
+5.2%
0.00%0.0%
Q1 2021$471,000
+21.7%
60,986
+3.1%
0.00%0.0%
Q4 2020$387,000
+4.3%
59,141
+5.9%
0.00%0.0%
Q3 2020$371,000
-30.0%
55,831
-12.2%
0.00%0.0%
Q2 2020$530,000
+14.0%
63,621
+4.9%
0.00%0.0%
Q1 2020$465,000
-10.2%
60,665
-2.7%
0.00%0.0%
Q4 2019$518,000
+14.6%
62,355
+1.9%
0.00%0.0%
Q3 2019$452,000
-33.1%
61,208
+1.5%
0.00%0.0%
Q2 2019$676,000
+8.9%
60,287
+4.3%
0.00%0.0%
Q1 2019$621,000
-30.5%
57,787
-2.3%
0.00%
-50.0%
Q4 2018$893,000
+27.9%
59,143
+56.7%
0.00%
+100.0%
Q3 2018$698,000
-17.6%
37,741
+1.9%
0.00%
-50.0%
Q2 2018$847,000
+2.8%
37,052
+28.0%
0.00%0.0%
Q1 2018$824,000
+35.7%
28,952
+0.7%
0.00%
+100.0%
Q4 2017$607,000
+1.2%
28,752
-12.9%
0.00%0.0%
Q3 2017$600,000
+19.0%
32,997
+1.5%
0.00%0.0%
Q2 2017$504,000
+33.3%
32,517
+48.4%
0.00%0.0%
Q1 2017$378,000
+63.6%
21,910
+4.1%
0.00%0.0%
Q4 2016$231,000
-14.4%
21,038
+22.1%
0.00%0.0%
Q3 2016$270,000
+77.6%
17,226
+15.4%
0.00%
Q2 2016$152,00014,9260.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q2 2016
NameSharesValueWeighting ↓
BVF INC/IL 5,803,700$25,130,0000.91%
Altium Capital Management LP 663,800$2,874,0000.79%
Rubric Capital Management LP 2,406,449$10,420,0000.49%
RTW INVESTMENTS, LP 6,029,700$26,109,0000.38%
Orbimed Advisors 3,214,509$13,919,0000.18%
TANG CAPITAL MANAGEMENT LLC 152,345$660,0000.13%
PLATINUM INVESTMENT MANAGEMENT LTD 980,085$4,244,0000.12%
Point72 Asset Management, L.P. 6,303,025$27,292,0000.11%
Sender Co & Partners, Inc. 40,720$176,0000.09%
Manteio Capital LLC 15,067$65,0000.08%
View complete list of CYTOMX THERAPEUTICS INC shareholders